Publicaciones en colaboración con investigadores/as de Universidad Autónoma de Madrid (15)

2024

  1. Potential protective role of let-7d-5p in atherosclerosis progression reducing the inflammatory pathway regulated by NF-κB and vascular smooth muscle cells proliferation

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 7

2022

  1. Implication of miR-155-5p and miR-143-3p in the Vascular Insulin Resistance and Instability of Human and Experimental Atherosclerotic Plaque

    International journal of molecular sciences, Vol. 23, Núm. 18

2018

  1. Chronic exercise improves mitochondrial function and insulin sensitivity in brown adipose tissue

    Frontiers in Physiology, Vol. 9, Núm. AUG

2015

  1. Updating experimental models of diabetic cardiomyopathy

    Journal of Diabetes Research, Vol. 2015

2013

  1. Factors involved in rosuvastatin induction of insulin sensitization in rats fed a high fat diet

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 23, Núm. 11, pp. 1107-1114

2009

  1. Leukotriene B4 enhances the activity of nuclear factor-κB pathway through BLT1 and BLT2 receptors in atherosclerosis

    Cardiovascular Research, Vol. 81, Núm. 1, pp. 216-225

2008

  1. Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndrome††Conflicts of interest: Drs. Egido and Tuñón have participated on advisory boards and have been invited speakers for Pfizer.

    American Journal of Cardiology, Vol. 102, Núm. 1, pp. 12-18

2007

  1. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis

    Journal of Pharmacology and Experimental Therapeutics, Vol. 320, Núm. 1, pp. 108-116

2006

  1. Overexpression of COX-2, Prostaglandin E Synthase-1 and Prostaglandin E Receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: Regulation by nuclear factor-κB

    Atherosclerosis, Vol. 187, Núm. 1, pp. 139-149

2005

  1. HMG-CoA reductase inhibitors reduce IκB kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells

    Journal of Cardiovascular Pharmacology, Vol. 45, Núm. 5, pp. 468-475

  2. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month

    Stroke, Vol. 36, Núm. 8, pp. 1796-1800

2004

  1. Estatinas, inflamación y lesión aterosclerótica

    Nefrologia, Vol. 24, Núm. SUPPL.4, pp. 17-20

  2. NF-κB Activation and Fas Ligand Overexpression in Blood and Plaques of Patients with Carotid Atherosclerosis: Potential Implication in Plaque Instability

    Stroke, Vol. 35, Núm. 2, pp. 458-463

  3. Propiedades anti-inflamatorias e inmunomoduladoras de las estatinas

    Nefrologia, Vol. 24, Núm. SUPPL.1, pp. 48-49

2002

  1. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells

    Atherosclerosis, Vol. 160, Núm. 1, pp. 49-58